Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.76 USD
Change Today +0.03 / 0.22%
Volume 52.4K
REPH On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (REPH) Snapshot

Open
$13.77
Previous Close
$13.73
Day High
$13.81
Day Low
$13.14
52 Week High
04/15/15 - $15.40
52 Week Low
12/16/14 - $2.36
Market Cap
107.9M
Average Volume 10 Days
84.6K
EPS TTM
$-1.95
Shares Outstanding
7.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECRO PHARMA INC (REPH)

Related News

No related news articles were found.

recro pharma inc (REPH) Related Businessweek News

No Related Businessweek News Found

recro pharma inc (REPH) Details

Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, engages in developing non-opioid therapeutics for the treatment of pain. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex to the treatment of chronic pain; and Fadolmidine(Fado) for post-operative and/or neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

5 Employees
Last Reported Date: 04/2/15
Founded in 2007

recro pharma inc (REPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.4K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $320.5K
Senior Vice President of Development and Secr...
Total Annual Compensation: $255.2K
Compensation as of Fiscal Year 2014.

recro pharma inc (REPH) Key Developments

Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM

Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.

Recro Pharma, Inc. Reports Financial Results for the First Quarter Ended March 31, 2015

Recro Pharma, Inc. reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, he c reported a net loss applicable to common shareholders of $4.1 million, or $0.53 per basic and diluted share, compared to a net loss applicable to common shareholders of $6.4 million, or $3.67 per basic and diluted share, for the comparable period in 2014.

Recro Pharma, Inc. Announces Update on On-Going Phase II Clinical Trial of Dex-In for Treatment of Acute Pain on Day 1 Following Surgery

Recro Pharma, Inc. announced that it had completed the prespecified interim analysis conducted on the company's Phase II, double-blind REC-14-013 trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1 following bunionectomy surgery. The purpose of the interim analysis was to allow for a sample size adjustment, if necessary, to maintain the ability to detect a difference in treatment effects between Dex-IN and placebo. The trial was expected to enroll approximately 200-250 patients. As a result of the interim analysis, the total enrollment for the trial was adjusted to approximately 170 patients. The Phase II trial is a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who meet the eligibility criteria are randomized to either a 50µg dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remain under observation for 48 hours at study centers. Patients are followed for 7 days after the initial dose of study medication. There is an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. The primary efficacy endpoint of the trial is the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints include use of opioid rescue medication, other pain parameters and opioid related side effects, as well as Patient Global Assessment (PGA) of pain control. Bunionectomy surgery generally involves an incision in the top or side of the big toe joint and the removal or realignment of soft tissue and bone. This is done to relieve pain and restore normal alignment to the joint. Bunionectomy surgery typically results in intense post-operative pain. In the past, drugs that have demonstrated analgesic effectiveness following bunionectomy surgery have frequently translated that analgesic success into other post-operative procedures that result in moderate to severe, acute pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REPH:US $13.76 USD +0.03

REPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REPH.
View Industry Companies
 

Industry Analysis

REPH

Industry Average

Valuation REPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit www.recropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.